Loading
CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.33, animal model 0.66, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma.
In plain words · CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription.
No product in this corpus aims at CDX2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CDX2: RNA tissue enriched (intestine 45 nTPM); high antibody staining in 4 normal tissues; highest cancer staining colorectal cancer (7 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Oesophageal cancer, Skin cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q99626; CIViC gene CDX2; IntOGen CDX2; Human Protein Atlas CDX2 tissue; Open Targets ENSG00000165556 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Inamori et al, Biochem. Biophys. Res. Commun, 1993, "Identification of homeobox genes expressed in human T-lymphocytes". Source.
Sources: HGNC HGNC:1806 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99626 (protein name, function text, keywords and locations (REST API)); CIViC gene CDX2 (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0)); Open Targets ENSG00000165556 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: melanoma 0.53, skin cancer 0.53, lung cancer 0.51 (GraphQL API, CC0)); IntOGen CDX2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription. Binds to and activates transcription of LPH. Activates transcription of CLDN2 and intestinal mucin MUC2. Binds to the 5'-AATTTTTTACAACACCT-3' DNA sequence in the promoter region of CA1 and activates CA1 transcription. Location: Nucleus (UniProt). Locus 13q12.2 (HGNC).
RNA: tissue enriched (intestine 45 nTPM), detected in some normal tissues.
Medium: Small intestine.
RNA group enriched: Colon Adenocarcinoma 84 pTPM, Rectum Adenocarcinoma 90 pTPM.
Medium only: carcinoid, pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CDX2" OR ABSTRACT:"CDX2" OR TITLE:"caudal type homeobox 2" OR ABSTRACT:"caudal type homeobox 2" OR TITLE:"Homeobox protein CDX-2" OR ABSTRACT:"Homeobox protein CDX-2" OR TITLE:"CDX3" OR ABSTRACT:"CDX3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDX2, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.